Table 5.
Comparison of Clinical Characteristics between Major Branch Retinal Vein Occlusion and Macular Branch Retinal Vein Occlusion.
| Major BRVO (34 eyes) | Macular BRVO (24 eyes) | P value | |
|---|---|---|---|
| Baseline measurements | |||
| LogMAR visual acuity | 0.31 ± 0.320 | 0.24 ± 0.173 | 0.269 |
| Foveal thickness (μm) | 528.0 ± 147.3 | 450.5 ± 120.8 | 0.023 |
| Total NPA (disc area) | 22.3 ± 17.2 | 1.42 ± 2.36 | <0.001 |
| Central macular NPA in SCP (mm2) | 1.64 ± 0.56 | 1.35 ± 0.62 | 0.271 |
| Central macular NPA in DCP (mm2) | 1.95 ± 0.68 | 1.51 ± 0.64 | 0.152 |
| 12 months after initial treatment | |||
| LogMAR visual acuity | 0.03 ± 0.18 | 0.04 ± 0.13 | 0.812 |
| Total NPA (disc area) | 50.8 ± 27.9 | 0.92 ± 2.11 | <0.001 |
| Central macular NPA in SCP (mm2) | 1.65 ± 0.58 | 1.51 ± 0.53 | 0.445 |
| Central Macular NPA in DCP (mm2) | 1.92 ± 0.70 | 1.70 ± 0.60 | 0.295 |
| 24 months after initial treatment | |||
| LogMAR visual acuity | 0.03 ± 0.19 | 0.03 ± 0.11 | 0.919 |
| Central macular NPA in SCP (mm2) | 1.52 ± 0.52 | 1.36 ± 0.46 | 0.310 |
| Central macular NPA in DCP (mm2) | 1.80 ± 0.54 | 1.67 ± 0.53 | 0.449 |
| Total number of ranibizumab injections administered | 5.4 ± 2.4 | 5.4 ± 2.5 | 0.994 |
| Occurrence of neovascular changes (%) | 6 (17.6%) | 0 (0%) | 0.030 |
BRVO = branch retinal vein occlusion; logMAR = logarithm of the minimum angle of resolution; NPA = retinal nonperfusion area; SCP = superficial capillary plexus; DCP = deep capillary plexus; Data are mean ± standard deviation unless otherwise indicated. The baseline measurements of optical coherence tomography angiography were obtained after the initial resolution of macular edema and macular hemorrhage.